TransCon Semaglutide: Validated Moiety, Zero Formulation Data, Elevated Competitive Bar

Ascendis Regains Rights to TransCon Technology from Novo Nordisk

Ascendis Pharma A/S announced it will regain exclusive rights to its TransCon technology-based products in metabolic and cardiovascular diseases, including once-monthly TransCon Semaglutide. This follows the termination of its collaboration agreement with Novo Nordisk A/S, which was announced in November 2024. Under the terms, all licenses granted to Novo Nordisk for these therapeutic areas will revert to Ascendis, with no continuing financial obligations between the parties. Ascendis plans to initiate multiple new programs in both rare and large metabolic and cardiovascular indications, including advancing TransCon Semaglutide for obesity and type 2 diabetes, aiming to establish best-in-class therapies.

• Ascendis Pharma has successfully terminated its collaboration agreement with Novo Nordisk A/S, originally announced in November 2024. This termination ensures that all exclusive rights to TransCon technology-based products in metabolic and cardiovascular diseases, including TransCon Semaglutide, will revert entirely to Ascendis, with no ongoing financial commitments for either party.
• With the regained rights, Ascendis is poised to launch multiple new development programs targeting both rare and large metabolic and cardiovascular indications. A key focus will be advancing once-monthly TransCon Semaglutide, an investigational GLP-1 receptor agonist prodrug, for potential treatments in obesity and type 2 diabetes.
• This strategic move aligns with Ascendis' Vision 2030 and its mission to deliver best-in-class therapies by applying its innovative TransCon technology platform. The company aims to address significant unmet medical needs across these therapeutic areas, building on its track record of three consecutive approved products.

Addressing Key Challenges in Metabolic and Cardiovascular Diseases

Despite meaningful advances in pharmacotherapy, several structural, clinical, and biological challenges continue to limit the effectiveness of treatment across metabolic and cardiovascular diseases. These limitations span disease heterogeneity, therapeutic inertia, adherence gaps, and residual risk that persists even with guideline-directed therapy.

• Residual cardiovascular risk despite LDL-C control: Even with intensive statin therapy, a substantial risk of atherosclerotic cardiovascular disease events remains. Elevated triglycerides serve as a marker of this residual risk, and triglyceride-rich lipoproteins and their cholesterol-enriched remnant particles are associated with atherogenesis — yet therapeutic strategies beyond LDL-C reduction remain underutilized in clinical practice.

• Therapeutic inertia in hypertension management: Hypertension remains inadequately controlled globally despite the availability of effective therapies and guideline recommendations. Barriers to optimal blood pressure control include physicians' limited attitudes toward implementing major international guideline recommendations, misconceptions about single-pill combinations, limited use of ambulatory blood pressure monitoring, and suboptimal patient engagement. In a cross-sectional study of hypertensive patients with metabolic syndrome, therapeutic inertia — defined as the proportion of patients without any change in antihypertensive treatment despite a lack of blood pressure control — was most common among endocrinologists (56%).

• Absence of proven curative treatment for HFpEF: Heart failure with preserved ejection fraction (HFpEF) represents nearly half of all heart failure cases globally, yet there is still no proven curative treatment. Diagnosing HFpEF in obese patients is particularly challenging due to overlapping comorbidities such as hypertension and diabetes, as well as the reduced reliability of traditional biomarkers such as N-terminal pro-B-type natriuretic peptide.

• Under-treatment of cardiometabolic risk factors in high-risk populations: In a cross-sectional study of clozapine-treated outpatients, 58.3% met criteria for metabolic syndrome, 55.9% had blood pressure meeting metabolic syndrome criteria, and 55.2% had elevated blood triglycerides — yet in the majority of individuals, cardiometabolic risk factors were untreated or under-treated.

• Adherence and persistence as determinants of real-world outcomes: In a population-based study of patients with type 2 diabetes and a history of myocardial injury, high adherence to SGLT2 inhibitor therapy was consistently associated with lower risk of cardiovascular events or death, with adjusted hazard ratios for high versus very low adherence ranging from 0.65 (95% CI: 0.52–0.82) in heart failure patients to 0.76 (95% CI: 0.62–0.93) in acute coronary syndrome patients. This dose-response relationship underscores that suboptimal adherence directly translates to worse clinical outcomes.

• Long-term weight regain following pharmacotherapy discontinuation: With GLP-1 receptor agonists such as semaglutide, long-term use was essential for sustained weight loss, as discontinuation led to significant weight regain — highlighting the chronic, maintenance-dependent nature of obesity pharmacotherapy and the challenge of sustaining cardiometabolic benefits over time.

Evaluating TransCon Semaglutide's Safety and Tolerability Profile

The knowledge base does not have sufficient information to answer this question.

Exploring Novel Targets for Ascendis's Metabolic & CV Pipeline

Recent research has identified a range of novel molecular targets across metabolic and cardiovascular disease areas, moving well beyond established pharmacological mechanisms. These emerging targets span lipid metabolism, cardiac sarcomere function, natriuretic peptide signaling, and incretin receptor biology, reflecting a broad and mechanistically diverse pipeline.

• Cardiac myosin modulation in heart failure: Both myosin inhibitors and myosin activators have emerged as promising therapeutic strategies for cardiomyopathies. Understanding the molecular basis of genetically determined cardiomyopathies — particularly those associated with heart failure — has enabled direct sarcomere modulation as a novel treatment approach, with relevance especially for patients with preserved or mildly reduced left ventricular ejection fraction.

• Natriuretic peptide receptor (NPR-A and NPR-B) and cGMP pathway augmentation: Therapeutic strategies targeting natriuretic peptide receptors and cyclic guanosine monophosphate (cGMP) signaling in heart failure include epigenetics, modulation of enzyme activity in natriuretic peptide synthesis, gene therapy, augmentation of soluble guanylate cyclase (sGC), phosphodiesterase (PDE) inhibition, nitrates, cGMP-dependent protein kinase modulation, synthetic and designer natriuretic peptides, and RNA therapy.

• ANGPTL3 inhibition for hyperlipidemia and atherosclerosis: Angiopoietin-like 3 (ANGPTL3), a liver-produced glycoprotein that inhibits lipoprotein lipase and endothelial lipase, has emerged as a novel target in lipoprotein metabolism. Pharmacological inactivation with the monoclonal antibody evinacumab results in a 50% reduction in LDL-C, including in patients with homozygous familial hypercholesterolemia (HoFH), via an LDL-receptor independent mechanism. Nucleic acid-based therapies — including antisense oligonucleotides (ASO) and small-interfering RNA (siRNA) — targeting ANGPTL3 are active areas of clinical investigation, with ANGPTL3 inhibition also demonstrating apolipoprotein B (apoB) lowering of up to 46%.

• PCSK9 inhibition and novel LDL-C-lowering agents: Evolocumab and alirocumab, monoclonal antibody PCSK9 inhibitors, lower LDL-C by approximately 60%. Inclisiran, a siRNA molecule inhibiting PCSK9 translation, reduces LDL-C by approximately 50% with twice-yearly subcutaneous dosing. Bempedoic acid, an ATP citrate lyase inhibitor, lowers LDL-C by approximately 18% alone and 38% when combined with ezetimibe.

• Multi-receptor incretin agonism for obesity and type 2 diabetes: Tirzepatide, a GIPR/GLP-1R dual agonist, and peptide 20, a GIPR/GLP-1R/GCGR triagonist, represent a class of multi-targeting agents designed to maximize metabolic benefits with reduced side effects. Cryo-electron microscopy structures of these agents bound to their respective receptors have elucidated key interactions of clinical relevance. Retention of glucagon function in triagonists is required to achieve advantage over GLP-1 monotherapy. Novel triagonist structures, including analogue P2-L4, have demonstrated low-nanomolar potency across GLP-1R, GCGR, and GIPR targets in vitro.

• ApoC-III inhibition for triglyceride lowering: Apolipoprotein C-III (ApoC-III) has been identified as a key regulator of triglyceride metabolism. Volanesorsen, an antisense therapy, is approved for patients with extremely elevated plasma triglyceride levels. GalNAc-conjugated oligonucleotide approaches targeting ApoC-III have shown moderate apoB reduction of up to approximately 30% in a phase 1/2a dose-finding study.

TransCon Semaglutide: Navigating the GLP-1 RA Landscape

The knowledge base does not have sufficient information to answer this question.

Ascendis Reclaims TransCon Semaglutide: A New GLP-1 Contender

Ascendis Pharma's decision to reclaim full rights to its TransCon technology in metabolic and cardiovascular diseases, including the promising TransCon Semaglutide, signals a bold strategic move into one of the pharmaceutical industry's most dynamic and lucrative therapeutic areas. This reacquisition positions Ascendis to directly challenge the established players in the GLP-1 receptor agonist market, a class of drugs that has revolutionized the treatment of type 2 diabetes and obesity.

The core of Ascendis's strategy lies in its proprietary TransCon platform, a polymer-drug conjugate technology designed to provide sustained release of active compounds. This approach has shown preclinical promise in other indications, such as achondroplasia with TransCon CNP, by maintaining therapeutic levels while avoiding the high peak concentrations that can lead to adverse effects. Applying this to semaglutide, a highly effective GLP-1 agonist known for its significant weight loss and glucose-lowering capabilities, could yield a once-monthly formulation that offers enhanced patient convenience and potentially a differentiated safety profile compared to existing weekly injections.

However, this ambitious undertaking is not without its challenges:

• The GLP-1 market is intensely competitive, with strong incumbents like weekly semaglutide and emerging dual agonists already demonstrating impressive clinical outcomes. Ascendis will need to present compelling data that clearly showcases the advantages of a once-monthly regimen, whether in terms of efficacy, safety, or patient preference.

• Developing and gaining regulatory approval for novel drug delivery systems, such as polymer-drug conjugates, can be complex, requiring rigorous clinical validation to overcome potential hurdles.

• While sustained release aims to mitigate side effects, the long-term tolerability of a once-monthly semaglutide, particularly concerning gastrointestinal events common with GLP-1s, will be under close scrutiny.

Beyond obesity and type 2 diabetes, the regained rights open doors for Ascendis to explore other high-value metabolic indications, such as NASH, where semaglutide is already in advanced trials and a significant unmet need persists. This strategic pivot could transform Ascendis into a key player in metabolic health, provided it can successfully navigate the competitive landscape and deliver on the promise of its innovative TransCon technology.